Myth 1: "Compounded semaglutide is the same as Ozempic / Wegovy / Rybelsus."
Verdict: False.
Same active ingredient (semaglutide). Different products. Compounded semaglutide is not FDA-approved as a finished drug product; Ozempic, Wegovy, and Rybelsus are. Excipients, concentration, container, and dose calibration may differ. The molecule's effect is the same; the labeling, manufacturing standards, and FDA approval status are not.
Myth 2: "All compounded semaglutide is the same."
Verdict: False.
Compounded semaglutide can be prepared by 503A licensed compounding pharmacies (USP <797> sterility framework, no cGMP requirement, patient-specific compounding) or by 503B FDA-registered outsourcing facilities (cGMP-compliant, FDA-inspected, can produce in bulk under specific rules). The product, standards, and supply chain differ meaningfully between the two. Additionally, salt forms of semaglutide (sodium, acetate) — which the FDA has flagged in warning letters — are NOT acceptable; only semaglutide base is.
Myth 3: "Compounded semaglutide is illegal."
Verdict: False — but more nuanced post-April 14, 2026.
Compounded semaglutide remains legal when (a) prepared by a licensed 503A pharmacy for an individual patient with a valid prescription, or (b) produced by a 503B FDA-registered outsourcing facility under the rules governing those facilities. The April 14, 2026 FDA action announced intent to restrict ingredients in mass-marketed compounded GLP-1 medications and to crack down on misleading direct-to-consumer marketing — particularly targeting salt-form preparations and operations whose volume doesn't match the patient-specific 503A standard. Compounded semaglutide base from FDA-registered API suppliers, dispensed by licensed pharmacies pursuant to valid prescriptions, remains lawful.
Myth 4: "Semaglutide and tirzepatide are basically the same drug."
Verdict: False.
Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GIP / GLP-1 receptor agonist — it activates two different receptors. Effect sizes differ (SURPASS-2 showed tirzepatide produces ~47% greater weight loss vs semaglutide 1 mg in T2D). Approved indications differ (Wegovy has CV indication; Zepbound has OSA indication). They are not interchangeable.
Myth 5: "Foundayo (orforglipron) is a generic Ozempic."
Verdict: False.
Foundayo is a different molecule. It is a small-molecule, non-peptide GLP-1 receptor agonist developed by Eli Lilly and FDA-approved in March 2026 under the Commissioner's National Priority Voucher pilot. Semaglutide is a peptide. They are distinct chemical entities. Foundayo is taken orally (not injectable), is not a generic of semaglutide, and is not produced by Novo Nordisk.
Myth 6: "If I stop semaglutide I'll keep the weight off."
Verdict: False, with caveats.
STEP-4 (Rubino et al., JAMA 2021) showed that patients who stopped semaglutide after 20 weeks of escalation regained much of the lost weight, while patients who continued the medication kept it off and even lost more. This is why obesity is now framed as a chronic disease requiring long-term therapy — comparable to how hypertension or T2D are managed. Some patients sustain weight loss with structured lifestyle change after a period on therapy, but the default expectation should be long-term continuation.
Myth 7: "Semaglutide doses are equivalent across products."
Verdict: False.
Ozempic maintenance doses go to 2.0 mg weekly. Wegovy goes to 2.4 mg weekly. Rybelsus tablets are 3, 7, or 14 mg daily (not interchangeable with subcutaneous on a per-mg basis due to oral bioavailability differences). Compounded preparations may be in different concentrations than branded; the dose value on a vial label is meaningful only if you also know the concentration. Always check the concentration before calculating an injectable dose.
Myth 8: "Everyone gets the same nausea / GI side effects."
Verdict: False.
STEP-1 reported nausea in 44% of semaglutide patients (vs 16% placebo). That means ~56% did NOT report nausea. Side effects are dose-dependent (worse at higher doses) and titration-dependent (worse during dose escalations, then settle). Individual susceptibility varies significantly. A patient who has poor tolerance can usually be managed by slowing the titration, holding at a lower dose, or splitting the dose schedule with the prescribing clinician.
Myth 9: "Semaglutide causes thyroid cancer in humans."
Verdict: Not established.
The boxed warning on the semaglutide class is based on rodent studies showing C-cell hyperplasia and medullary thyroid carcinoma in lab animals. Human data are limited but do not establish a clear causal link to date. Out of an abundance of caution, semaglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). Patients without these contraindications do not have evidence of meaningfully elevated MTC risk from semaglutide use.
Myth 10: "Compounded semaglutide is cheaper because it's lower quality."
Verdict: False (with important framing).
Compounded semaglutide is cheaper because the supply chain, manufacturing model, and regulatory pathway are different from branded — not because the active ingredient is inferior. The same molecule (semaglutide base) is used by both compounded and branded operations; the branded products carry the regulatory and supply-chain costs of FDA approval, cGMP manufacturing, pen device assembly, and brand marketing. Compounded preparations bypass those costs (and the corresponding regulatory protections). The right way to think about this: the molecule's therapeutic effect is comparable; the difference is FDA approval status, manufacturing standards, and the specific product quality controls applied. Quality varies meaningfully across compounded providers — which is why Pillar 2 of the v3.0 rubric scores pharmacy traceability and certificates of analysis.